Skin Affecting Patents (Class 514/18.6)
-
Patent number: 8790688Abstract: A wound care device for local treatment of pain in a wound is provided. The device comprises an active pain relieving composition, which can also be an anti-inflammatory agent. The wound care device is suitable for treatment of pain in open wounds. The device can include small amounts of pain relieving compositions that are effective in relieving pain at the wound while not resulting in any systemic effects. The device may be in the form of a wound dressing, and the pain relieving composition may be delivered to the wound through a controlled release system.Type: GrantFiled: December 19, 2002Date of Patent: July 29, 2014Assignee: Coloplast A/SInventors: Gitte Juel-Friis, Tine Richter-Friis, Truels Sterm Larsen
-
Publication number: 20140200185Abstract: The present invention provides a method for the treatment of ocular or dermal diseases and/or conditions, e.g. an aqueous deficient dry eye state, uveitis or phacoanaphylactic endophthalmitis in an eye, or balanitis, psoriasis, or atopic dermatitis of the skin, said method comprising administering, topically to the eye or the skin, a therapeutically effective amount of a novel cyclosporin A derivative selected from the group consisting of compounds represented by the formula: wherein R1 is S-Alk-R wherein Alk is an alkylene linkage, preferably a methylene or poly methylene linkage, e.g. a C2 to C6 polymethylene linkage, or a polyalkenylene linkage, e.g. a C3 to C6 alkenylenyl linkage, R is R is —N?C(NR3R4)(NR5R6) or —NR2[(NR3R4)C?NR5], i.e. guanidines or —N?C(R8)(NR9R10), i.e.Type: ApplicationFiled: March 17, 2014Publication date: July 17, 2014Applicant: Allergan, Inc.Inventor: Michael E. Garst
-
Publication number: 20140200531Abstract: Aspects of the present invention concern the discovery of a transdermal delivery composition that can deliver low, medium and high molecular weight pharmaceuticals and cosmetic agents. Embodiments include transdermal delivery compositions with therapeutic and cosmetic application, transdermal delivery devices for providing said transdermal delivery compositions to subjects in need thereof, and methods of making and using of the foregoing.Type: ApplicationFiled: December 19, 2013Publication date: July 17, 2014Applicant: JRX Biotechnology, Inc.Inventors: Frederick Jordan, Geoff E. Dolbear
-
Publication number: 20140194365Abstract: C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung.Type: ApplicationFiled: March 12, 2014Publication date: July 10, 2014Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Carol A. Feghali-Bostwick, Yukie Yamaguchi
-
Patent number: 8765689Abstract: Peptide compounds of the general formula (I) R1-(AA)n-X1—X2-Arg-Glu-Met-Asn-Trp-X3-(AA)p-R2 modulating the survivin protein are described. Furthermore, cosmetic or pharmaceutical compositions, including at least one peptide of the general formula (I), in a physiologically acceptable medium are described. Additionally, methods for treating the cutaneous signs of ageing and photo-ageing, treating the skin against external aggressions, and limiting hair loss and/or stimulating hair growth are described.Type: GrantFiled: January 13, 2011Date of Patent: July 1, 2014Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8765673Abstract: The present invention provides methods for promoting wound healing and/or reducing scar formation, by administering to an individual in need thereof one or more of the heat shock protein 20-derived polypeptides disclosed herein.Type: GrantFiled: January 4, 2012Date of Patent: July 1, 2014Assignee: Arizona Board of RegentsInventors: Colleen Brophy, Alyssa Panitch, Catherine Parmiter, Elizabeth Furnish, Padmini Komalavilas
-
Patent number: 8758770Abstract: Methods and compositions for the enteral treatment of autoimmune disease such a multiple sclerosis with polypeptide therapeutics. Enteral therapeutics comprise monomeric alpha-MSH polypeptides such as ACTH. Therapeutic formulations of the invention may be used to reduce the incidence or severity of autoimmune disease. For instance methods for the oral treatment of multiple sclerosis with alpha-MSH and ACTH are described.Type: GrantFiled: October 4, 2010Date of Patent: June 24, 2014Assignee: Research Development FoundationInventor: Staley A. Brod
-
Publication number: 20140162959Abstract: The invention relates to novel topical pharmaceutical compositions in which the active agent is a cyclic depsipeptide of formula (II) and to methods for manufacturing such compositions.Type: ApplicationFiled: February 4, 2014Publication date: June 12, 2014Applicant: NOVARTIS AGInventor: Claire HAUG
-
Publication number: 20140155315Abstract: The invention provides a synthetic polypeptide of Formula I? (SEQ ID NO: 1): X1-X2-X3-R—X5-X6-X7-X8-X9-X10-X11-X12-X13??I or an amide, an ester or a salt thereof, wherein X1, X2, X3, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia.Type: ApplicationFiled: November 18, 2013Publication date: June 5, 2014Applicant: NOVARTIS AGInventors: Frédéric Zecri, Kayo Yasoshima, Philipp Grosche, Jun Yuan, Hongjuan Zhao
-
Patent number: 8741848Abstract: The present invention relates to a pharmaceutical composition that comprises polymeric microspheres containing epidermal growth factor (EGF) for the application, by the parenteral route, into the lower limbs of diabetic patients with cutaneous chronic ischemic ulcerative wounds. The pharmaceutical composition described herein, in contrast with the state of the art, is useful because reduce the administration frequency during the treatment and allows for the healing of the ulcerative wounds in a shorter time interval with respect to the injection of equivalent quantities of non-encapsulated EGF.Type: GrantFiled: January 29, 2007Date of Patent: June 3, 2014Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Vivian Maria Sáez Martinez, Rolando Páez Meireles, Jorge Amador Berlanga Acosta, Blas Yamir Betancourt Rodriguez, José Ángel Ramón Hernández
-
Publication number: 20140148394Abstract: The various embodiments relate to peptide antagonists of ?c-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21). The ?c-cytokines are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of ?c-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Traditional approaches to inhibiting ?c-cytokine activity involve raising neutralizing antibodies against each individual ?c-cytokine family member/receptor subunit. However, success has been limited and often multiple ?c-cytokine family members co-operate to cause the disease state. Combinatorial use of neutralizing antibodies raised against each factor is impractical and poses an increased risk of adverse immune reactions.Type: ApplicationFiled: January 17, 2012Publication date: May 29, 2014Applicant: BIONIZ, LLCInventors: Yutaka Tagaya, Nazli Azimi
-
Publication number: 20140142042Abstract: A combination of a prostaglandin EP4 agonist and an effective amount of: a prostaglandin EP2 agonist, a skin growth factor, a small peptide, a small inhibitory RNA targeting excess chronic inflammation or fibrosis, a cytokine with beneficial anti-inflammatory activity, an adenosine A2a receptor agonist, an anti-oxidant, or a combination thereof, may be used to treat skin wounds or scars.Type: ApplicationFiled: November 13, 2013Publication date: May 22, 2014Applicant: Allergan, Inc.Inventors: Guang L. Jiang, Robert M. Burk, Wha-Bin Im, Larry A. Wheeler
-
Patent number: 8729028Abstract: Disclosed are a noggin-derived peptide and a composition containing the same for promoting hair growth, improving skin conditions, providing anti-inflammatory function, or preventing or treating bone diseases. The disclosed noggin-derived peptide performs a function identical or similar to that of natural human noggin and is superior in stability and skin permeability as compared thereto. The composition containing the peptide of the present disclosure as an active ingredient exhibits remarkably superior effects in treating, preventing or improving growth factor-related symptoms, e.g. hair loss, skin conditions or cut, or treating, preventing or improving growth factor overexpression-related symptoms. Therefore, the superior activity and stability of the peptide of the present disclosure are greatly advantageous in application to medicine, quasi-drugs and cosmetics.Type: GrantFiled: November 24, 2009Date of Patent: May 20, 2014Assignee: Caregen Co., Ltd.Inventors: Young Ji Chung, Young Deug Kim, Eun Mi Kim, Sang Su Song, Il Hong, Kyoung Mi Cho, Su Mi Kim, Sang Min Han
-
Patent number: 8722627Abstract: A peptidic hydrolyzate enriched in bioactive peptides is disclosed that is a proteasome activator. Cosmetic and pharmaceutical compositions are disclosed that include the peptidic hydrolyzate enriched in bioactive peptides in a physiologically acceptable medium. Also disclosed are methods for depigmenting, lightening and/or whitening the skin and treating hyperpigmentation blemishes as well as cutaneous signs due to photo-aging by administering the cosmetic compositions or pharmaceutical compositions.Type: GrantFiled: April 22, 2010Date of Patent: May 13, 2014Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8722618Abstract: IL4/IL13-binding proteins comprise binding domains, which inhibit IL4/IL13 binding to IL4Ralpaha and common gamma chain complexes (Type 1) and inhibit IL4 binding to IL4Ralpha and IL13Ralpha1 complexes (Type 2), and IL13 binding to IL13Ralpha1 and/or IL13Ralpha2, are useful in the treatment of cancer, inflammatory, and other pathological conditions, such as allergic or fibrotic conditions, especially pulmonary conditions.Type: GrantFiled: April 27, 2012Date of Patent: May 13, 2014Assignee: Janssen Biotech, Inc.Inventors: Steven Jacobs, Karyn O'Neil, Michael Baumann, Gaby Sennhauser
-
Patent number: 8716232Abstract: C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung.Type: GrantFiled: July 10, 2013Date of Patent: May 6, 2014Assignee: University of Pittsburgh— of the Commonwealth System of Higher EducationInventors: Carol A. Feghali-Bostwick, Yukie Yamaguchi
-
Patent number: 8710010Abstract: Peptides with general formula (I): R1-AA1-AA2-AA3-AA4-R2 its stereoisomers, mixtures thereof, and its cosmetically or pharmaceutically acceptable saits, a method of preparation, cosmetic or pharmaceutical compositions containing them and their use for the treatment and/or care of conditions, disorders and/or pathologies of the skin, mucous membranes, scalp and/or hair.Type: GrantFiled: October 2, 2009Date of Patent: April 29, 2014Assignee: Lipotec, S.A.Inventors: Wim Van Den Nest, Nuria Almiñana Domenech, Juan Cebrián Puche, Cristina Carreño Serraïma
-
Patent number: 8710011Abstract: Peptides of general formula (I): R1-Wp-Xn-AA1-AA2-AA3-AA4-Ym-R2 their stereoisomers, mixtures thereof, and/or their cosmetically or pharmaceutically acceptable salts, a method of preparation, cosmetic or pharmaceutical compositions containing them and their use for the treatment, prevention and/or care of conditions, disorders and/or diseases of the skin, mucous membranes and/or scalp.Type: GrantFiled: February 16, 2010Date of Patent: April 29, 2014Assignee: Lipotec, S.A.Inventors: Nuria Garcia Sanz, Wim Van Den Nest, Cristina Carreno Serraima, Antonio Ferrer Montiel, Juan Cebrian Puche, Nuria Alminana Domenech
-
Publication number: 20140113868Abstract: The present invention relates to a peptide analogue or a pharmaceutically acceptable salt thereof with excellent moisturizing effect, and use thereof for moisturization. More specifically, the present invention relates to a novel peptide analogue or a pharmaceutically acceptable salt thereof, a method for preparation thereof, a moisturizing cosmetic composition comprising the same as an active ingredient, and a pharmaceutical composition for prevention and treatment of xeroderma.Type: ApplicationFiled: May 22, 2012Publication date: April 24, 2014Applicant: INCOSPHARM CORPORATIONInventors: Kee-Don Park, Chae-Jin Lim, Seok-Jeong Yoon, Seon-Deok Kwon
-
Patent number: 8697656Abstract: The present invention concerns a peptide of following formula I: R being a side chain having at least one heteroatom selected from sulfur, nitrogen and oxygen in a carbonyl form (C?O); R1 being either H or a lipophilic chain; R2 being either OH or a lipophilic chain. More particularly the present invention concerns a cosmetic composition comprising a peptide as recited above and a physiologically acceptable medium. Results on the activity of the compounds are obtained and on the general state of the skin and its appendages, in particular via the stimulation of extracellular matrix components.Type: GrantFiled: January 15, 2010Date of Patent: April 15, 2014Assignee: SEDERMAInventors: Arnaud Fournial, Philippe Mondon, Olivier Peschard
-
Patent number: 8697652Abstract: This invention relates to the cosmetic use of at least one compound of formula (I) wherein A1 is the radical corresponding to D- or L-Ser A2 is the radical corresponding to D- or L-Asp or Glu, A3 is the radical corresponding to D- or L-Lys, Arg or Orn, A4 is the radical corresponding to D- or L-pro, R1, R2 and R3 are as defined in the claims as anti-aging and restructuring agents.Type: GrantFiled: June 22, 2005Date of Patent: April 15, 2014Assignee: Centre National de la Recherche Scientifique (CNRS)Inventors: Joanna Bakala, Jean-Yves Lallemand, Jian-Miao Liu, Jérôme Bignon
-
Patent number: 8685391Abstract: Dermatological and cosmetic compositions and methods are provided to reduce the appearance of biological and/or environmentally-caused aging.Type: GrantFiled: September 6, 2012Date of Patent: April 1, 2014Assignee: Jan Marini Skin Research, Inc.Inventor: Jan Marini
-
Patent number: 8685927Abstract: A cosmetic or pharmaceutical composition that includes a peptide hydrolyzate which is enriched in soothing bioactive peptide in a physiologically acceptable medium is described. Methods for applying such compositions to the skin are also described, in particular where the active principle activates 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) reductase in skin cells to treat skin irritations.Type: GrantFiled: April 15, 2010Date of Patent: April 1, 2014Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20140087994Abstract: Template-fixed ?-hairpin peptidomimetics of the general formula wherein Z is a template-fixed chain of 12 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to selectively inhibit the growth of or to kill microorganisms such as Pseudomonas aeruginosa. They can be used as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials, or as medicaments to treat or prevent infections. These ?-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and solution phase synthetic strategy.Type: ApplicationFiled: November 7, 2013Publication date: March 27, 2014Applicants: Universitaet Zuerich, POLYPHOR LTD.Inventors: Steven J. DEMARCO, Wim Vrijbloed, Ricardo Dias, John Anthony Robinson, Nityakalyani Srinivas, Frank Gombert, Daniel Obrecht
-
Publication number: 20140086855Abstract: The present invention provides combined use of a carnosinase inhibitor with L-carnosine and its related substance, and a composition containing the same, which are useful for treatment or prevention of various diseases, improvement of health conditions, improvement of exercise ability, improvement of skin health, prevention of the side effects of alcohol drinking and the like in mammals including human.Type: ApplicationFiled: December 2, 2013Publication date: March 27, 2014Applicant: INNOVATIVE VISION PRODUCTS, INC.Inventors: Mark BABIZHAYEV, Kanji MEGURO
-
Publication number: 20140087993Abstract: Disclosed here is the rational design and use of potent and specific GPCR antagonist pepducins based on GPCR regions such as the third intracellular loop and adjacent regions.Type: ApplicationFiled: April 9, 2012Publication date: March 27, 2014Applicant: TUFTS MEDICAL CENTER, Inc.Inventors: Athan Kuliopulos, Lidija Covic
-
Publication number: 20140088015Abstract: The invention provides for a mucin3 polypeptide, a polypeptide including a mucin3 EGF like domain, and nucleic acids encoding such polypeptides. The invention also provides for methods of treating an individual that has or is at risk of developing a disease or condition of the alimentary canal using such polypeptides or nucleic acids.Type: ApplicationFiled: April 26, 2013Publication date: March 27, 2014Inventors: Samuel B. Ho, Laurie L. Shekels
-
Publication number: 20140086981Abstract: Peptides of general formula (I): R1—Wn—Xm-AA1-AA2-AA3-AA4-AA5-AA6-Yp—Zq—R2 their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, a preparation process, cosmetic or pharmaceutical compositions which contain them and their use in the treatment and/or care of conditions, disorders and/or diseases which improve or are prevented by PGC-1? modulation.Type: ApplicationFiled: March 23, 2012Publication date: March 27, 2014Inventors: José María García Antón, Nuria Almiñana Domenech, Antonio Vicente Ferrer Montiel
-
Patent number: 8679477Abstract: The subject matter provided herein relates to method for inhibiting or mitigating scar formation in a wound of the skin, by increasing the concentration of SDF-1 in, or proximate to, the wound. As described herein SDF-1 protein or an SDF-1 expression vector can be administered to a wound or the area proximate a wound by providing a therapeutically effective amount of SDF-1 protein or an SDF-1 expression vector.Type: GrantFiled: October 12, 2012Date of Patent: March 25, 2014Assignees: The Cleveland Clinic Foundation, Juventas Therapeutics, Inc.Inventors: Marc S. Penn, Matthew Kiedrowski, Rahul Aras, Joseph Pastore
-
Patent number: 8680054Abstract: The invention relates to novel topical pharmaceutical compositions in which the active agent is a cyclic depsipeptide of formula (II) and to methods for manufacturing such compositions.Type: GrantFiled: April 12, 2012Date of Patent: March 25, 2014Assignee: Novartis AGInventor: Claire Haug
-
Patent number: 8673858Abstract: The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.Type: GrantFiled: December 21, 2012Date of Patent: March 18, 2014Assignee: Soricimed Biopharma Inc.Inventors: John M. Stewart, Bradley J. Steeves, Karl Vernes
-
Patent number: 8674072Abstract: A peptidic hydrolyzate enriched in bioactive peptide, capable of reinforcing the skin barrier function and stimulating epidermal differentiation is described. Additionally, a cosmetic and/or pharmaceutical composition that includes a physiologically acceptable medium and the peptidic hydrolyzate as active principle are described. The cosmetic composition activates the HMG-CoA reductase in the cutaneous cells and treats the cutaneous signs of aging and photo-aging.Type: GrantFiled: April 15, 2010Date of Patent: March 18, 2014Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8673859Abstract: It has been discovered that granulocyte macrophage colony stimulating factor (“GM-CSF”) promotes migration of activated (but not differentiating) keratinocytes to wound sites. It was also discovered that GM-CSF increases the quantity and improves the quality of collagen. This growth factor specifically increases migration of keratinocytes of the “wound” phenotype but does not have significant effects upon differentiated keratinocytes. Examples demonstrate reversal of skin impairment in multiple animal models of diabetic skin imparment when provided in an effective amount over an effective time period. The examples also demonstrate the efficacy of the formulations in cosmetic applications.Type: GrantFiled: March 20, 2008Date of Patent: March 18, 2014Assignee: New York UniversityInventors: Harold Brem, Marjana Tomic
-
Publication number: 20140072613Abstract: The described invention provides compositions, dressings and methods for treating a cutaneous scar in a subject. The compositions of the derived invention contains a pharmaceutical composition comprising a therapeutic amount of a Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2) inhibitor comprising an MK2 polypeptide inhibitor or a functional equivalent thereof, and a pharmaceutically acceptable carrier.Type: ApplicationFiled: March 14, 2013Publication date: March 13, 2014Inventors: Cynthia Lander, Caryn Peterson, Colleen Brophy
-
Publication number: 20140066380Abstract: Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.Type: ApplicationFiled: August 7, 2013Publication date: March 6, 2014Applicant: HELIX BIOMEDIX, INC.Inventors: Scott M. HARRIS, Timothy J. FALLA, Lijuan ZHANG
-
Publication number: 20140065094Abstract: The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.Type: ApplicationFiled: December 27, 2012Publication date: March 6, 2014Applicant: Creabillis Therapeutics S.P.A.Inventors: Silvio TRAVERSA, Chiara LORENZETTO, Valentina MAINERO, Sebastiano MORENA, Silvano FUMERO, Luca BECCARIA
-
Patent number: 8663617Abstract: The current invention relates to methods and compositions for the treatment of wounds in a mammalian subject. Particularly, the invention relates to novel polypeptides and encoding nucleic acids that stimulate keratinocyte and endothelial cell motility and/or proliferation.Type: GrantFiled: October 16, 2012Date of Patent: March 4, 2014Assignee: Tufts UniversityInventor: Ira M Herman
-
Publication number: 20140057831Abstract: The invention provides methods and compositions for inhibiting and/or reversing fibrosis. The invention further provides peptides and polypeptides which are BMP agonists which trigger BMP signaling and inhibit and/or reverse EMT in a cell or tissue.Type: ApplicationFiled: July 19, 2012Publication date: February 27, 2014Applicant: Thrasos Innovation, Inc.Inventors: Dattatreyamurty Bosukonda, Peter Keck
-
Publication number: 20140056964Abstract: Methods of promoting wound healing in a subject is disclosed. The method include applying a Granzyme B (Granzyme B) inhibitor to the wound. The wound may be a skin wound. The Granzyme B inhibitor may be comprised of nucleic acids, or peptides, including but not limited to antibodies, or small molecules.Type: ApplicationFiled: December 6, 2011Publication date: February 27, 2014Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Paul R. Hiebert, Darryl A. Knight, David J. Granville, Wendy A. Boivin, Dawn M. Cooper
-
Patent number: 8658599Abstract: A method to inhibit the formation of skin tumors at early stages and their subsequent progression to carcinoma in a mammal is described, the method including the topical application to the mammal's skin of a composition that includes a therapeutically effective amount of disitertide, together with pharmaceutically acceptable carriers or diluents.Type: GrantFiled: March 4, 2010Date of Patent: February 25, 2014Assignee: Digna Biotech, S.L.Inventors: Raul Insa Boronat, Miguel Quintanilla Avila, Javier Dotor De Las Herrerías
-
Patent number: 8653031Abstract: We describe preparation of compounds of an AT1 receptor antagonist(s) and Angiotensin (1-7), for example, Angiotensin-(1-7) losartanate and analogues thereof, and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products. Cyclodextrins and derivatives thereof may be used for the micro-encapsulation of compounds, for example, Angiotensin (1-7) losartanate, liposomes and biodegradable polymers and/or mixtures of these systems and/or derivative products for the obtainment of nano- or microparticles as controlled or sustained release devices of Ang-(1-7) losartanate and analogues and/or mixtures thereof. The compounds may be used as agents for treating or preventing hypertension, cardiovascular diseases, heart hypertrophy, heart failure, coronary diseases, such as angina pectoris, endothelial disorder or endothelial lesions, as a consequence, for example, of atherosclerosis processes or in association with diabetes mellitus.Type: GrantFiled: October 30, 2006Date of Patent: February 18, 2014Assignee: Universidade Federal de Minas GeraisInventors: Rubén Dario Sinisterra Millán, Cynthia Fernades Ferreira Santos, Robson Augusto Souza Dos Santos, Ivana Silva Lula, Frederico Barros De Sousa, Pedro Pires Goulart Guimaraes, Angelo Márcio Leite Denadai
-
Publication number: 20140045766Abstract: Methods of restoring the circadian rhythm and resynchronizing the biological clock of cells are described. The methods include topically applying a topical composition comprising a cosmetically acceptable medium and an effective quantity of a peptide compound of general formula (I), R1-(AA)n-X1-Ser-Thr-Pro-X2-(AA)p-R2, to skin or skin appendages to be treated.Type: ApplicationFiled: July 5, 2013Publication date: February 13, 2014Applicant: ISP INVESTMENTSInventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20140044649Abstract: There is described a material comprising tapes, ribbons, fibrils or fibres characterized in that each of the ribbons, fibrils or fibres have an antiparallel arrangement of peptides in a ?-sheet tape-like substructure.Type: ApplicationFiled: October 24, 2013Publication date: February 13, 2014Applicant: UNIVERSITY OF LEEDSInventors: Neville Boden, Amalia Aggeli, Eileen Ingham, Jennifer Kirkham
-
Publication number: 20140037634Abstract: The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates ?CD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon ?CD3/?GITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed. In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g.Type: ApplicationFiled: May 24, 2013Publication date: February 6, 2014Inventors: Randolph J. Noelle, Li Wang
-
Patent number: 8642646Abstract: The present invention relates to a method and composition for treating acne using lignan compounds represented by Formula 1. More particularly, the invention relates to an antibacterial composition against acne-causing bacteria, containing lignan compounds represented by Formula 1, as well as a method for treating acne using the same. The lignan compounds represented by Formula 1 are excellent not only in the antibacterial activity of inhibiting the growth of acne-causing bacteria, but also in thermal stability. Accordingly, the lignan compounds may be useful as antibacterial agents against the acne-causing bacteria, and acne treatment agents.Type: GrantFiled: January 7, 2005Date of Patent: February 4, 2014Assignees: New Tree Industry Co., Ltd.Inventors: Jae-Kwan Hwang, Jae-Youn Chung, Hee-Chul Chung, Kyung-Min Park
-
Patent number: 8642553Abstract: The invention relates to a composition containing an extract of seeds of Acacia macrostachya. Advantageously the composition is cosmetic, pharmaceutical, dermatological or nutraceutical. The invention also relates to a method for extracting a Acacia macrostachya seed extract, as well as to the resulting extract. The invention further relates to one such composition or one such extract for use in the prevention or treatment of disorders and diseases affecting the skin, mucosae or appendages, for use in the prevention or treatment of vascular disorders and for use in the prevention or treatment of adipose tissue alterations. Moreover, the invention relates to a method for cosmetic care of the Skin, appendages and mucosae in order to improve the condition or appearance thereof, comprising the administration of one such composition or one such extract.Type: GrantFiled: November 30, 2010Date of Patent: February 4, 2014Assignee: Laboratoires ExpanscienceInventors: Philippe Msika, Alex Saunois, Sophie Leclere-Bienfait, Caroline Baudoin
-
Publication number: 20140031296Abstract: The present invention relates to new peptides and to use thereof, in particular for treatment and/or prevention of infections, inflammations, pain, wounds, scar and/or tumours.Type: ApplicationFiled: January 25, 2012Publication date: January 30, 2014Applicant: PERGAMUM ABInventors: Margit Mahlapuu, Camilla Björn, Veronika Sjöstrand, Björn Walse, Bo Svenson
-
Publication number: 20140011730Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.Type: ApplicationFiled: September 12, 2013Publication date: January 9, 2014Applicant: Ipsen Pharma S.A.S.Inventors: Zheng Xin DONG, Daniel B. DEOLIVEIRA, Jeanne Mary COMSTOCK
-
Publication number: 20140005116Abstract: Due to a long-standing interest in scar reduction, alanyl-glutamine was tested for ability to treat keloid scars, despite the difficulties associated with delivering compounds above a certain size threshold across the skin barrier to the dermis where new skin is formed. Surprisingly, it was found that a dermal application formulation of alanyl-glutamine was effective in reducing the severity and/or preventing the formation of keloid scars.Type: ApplicationFiled: June 28, 2011Publication date: January 2, 2014Applicant: ADE THERAPEUTICS INC.Inventors: Adebola O.E. Obayan, Sanjeev Singh, Brenda Collen Joyce Yuzdepski
-
Publication number: 20140004130Abstract: Peptides, modified peptides and antibody or antibody fragment, which inhibit the activity of MIA (Melanoma Inhibitory Activity), for detecting, preventing and curing vitiligo are disclosed.Type: ApplicationFiled: March 12, 2012Publication date: January 2, 2014Inventor: Matteo Bordignon